1365-2222/asset/cea_left.gif?v=1&s=676c5dd6c41538d1202eb686abd82748c570d4d8)
1365-2222/asset/cea_centre.gif?v=1&s=4761aeed79a4957313f41ba37276a359d407e600)
1365-2222/asset/cea_right.gif?v=1&s=f089a0803409931b9630fc86f2f8b0dc887deb4b)
A steroid sparing effect of ketotifen in steroid-dependent asthmatics
Article first published online: 27 APR 2006
DOI: 10.1111/j.1365-2222.1980.tb02132.x
1365-2222/asset/cover.gif?v=1&s=363d6ac7042b7535760df61b7393fd8e0a08e85f "Clinical & Experimental Allergy")
Additional Information
How to Cite
LANE, D. J. (1980), A steroid sparing effect of ketotifen in steroid-dependent asthmatics. Clinical & Experimental Allergy, 10: 519–525. doi: 10.1111/j.1365-2222.1980.tb02132.x
Publication History
- Issue published online: 27 APR 2006
- Article first published online: 27 APR 2006
- Received 25 July 1979; accepted for publication 16 January 1980
- Abstract
- References
- Cited By
Summary
In a multicentre, double-blind trial, the steroid sparing effect of a new anti-anaphylactic agent ketotifen was assessed against placebo in eighty-six steroid-dependent asthmatics. Mean reduction in total daily prednisolone dosage in patients on ketotifen was 4.0 ± 3.6 mg compared to 1.7 ± 2.8 mg on placebo, a result significantly in favour of the active drug (P <0.01). This suggests that ketotifen has a place similar to that of disodium cromoglycate or steroid aerosols in the managment of steroid-dependent asthmatics. It has the advantage of requiring only twice-daily oral administration.